Imagine surviving a rare, life-threatening drug reaction, only to face years of physical, emotional, and social challenges long after leaving the hospital. This is the stark reality for survivors of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), as revealed by a groundbreaking study published in JAMA Dermatology. But here's where it gets even more eye-opening: while most research focuses on the acute phase of these conditions, this study dives into the often-overlooked aftermath, shedding light on the struggles survivors face once they return home.
Researchers from Vanderbilt University Medical Center's Center for Drug Safety and Immunology (CDSI), in partnership with the VUMC Qualitative Research Core, conducted one of the largest qualitative studies in the U.S. to explore the long-term effects of SJS/TEN from the patients' perspective. SJS and TEN occur when a medication triggers the immune system to attack the body’s skin and mucous membranes, leading to severe and sometimes fatal reactions. Yet, the story doesn’t end with hospital discharge—far from it.
Through in-depth interviews, survivors shared their experiences, painting a vivid picture of the challenges they face. And this is the part most people miss: many felt abandoned after leaving the hospital, with little to no guidance on managing the physical and psychological scars left behind. Skin conditions, visual impairments, flashbacks, anxiety, and depression were just the tip of the iceberg. What started as gratitude for survival often morphed into isolation, mistrust, and chronic fear of medications.
"By collaborating with experts in qualitative research and behavioral science, we were able to truly listen to patients in their own words," explained senior author Elizabeth Phillips, MD, director of the CDSI. "Their stories are both powerful and heart-wrenching, revealing the invisible aftermath of a disease that many clinicians may encounter only once in their careers."
The study highlights a glaring gap in care: survivors are often discharged without a clear plan for managing their long-term needs. Here’s the controversial part: Is it enough to save a life if we leave survivors to navigate years of suffering alone?** Lead author Michelle Martin-Pozo, Ph.D., emphasizes the urgent need for coordinated care, including mental health support, vision follow-ups, and education for both patients and families. "Survivors need to know what to expect and that they’re not alone," she said.
Improving support for SJS/TEN survivors will require systemic changes: better physician education, multidisciplinary follow-up, and integrating patient voices into care design. But the question remains: Are we doing enough to address the silent struggles of these survivors? What do you think? Share your thoughts in the comments—this is a conversation that needs to happen.
Reference: Michelle D. Martin-Pozo et al, Recovering From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, JAMA Dermatology (2025). DOI: 10.1001/jamadermatol.2025.4345. Link to study.
